MRNA Gets Positive CHMP Opinion for Updated COVID-19 Jab

Moderna, Inc. (MRNA) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency's (EMA) has rendered a positive opinion recommending marketing authorization for its updated formulation of the mRNA-based COVID-19 vaccine, Spikevax, targeting the variant JN.1. The CHMP recommended marketing approval to Spikevax, targeting the variant JN.1, for active immunization to prevent COVID-19 in individuals aged six months and above. Pending a decision from the European Co ...